Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings

Quick Read Tempus AI (TEM) launched an AI algorithm identifying cancer patients responsive to platinum-based chemotherapy using RNA analysis. Tempus reported preliminary Q4 revenue of $367M, up 83% year-over-year. Total contract value exceeded $1.1B. Analysts set a consensus target of $85.69 for Tempus with nearly 50% upside. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. Tempus AI, Inc. (NASDAQ:TE ...